• Fri, February 25, 2022

Matthew Kaplan Maintained (UTHR) at Strong Buy with Decreased Target to $203 on, Feb 25th, 2022

Matthew Kaplan of Ladenburg Thalmann, Maintained "United Therapeutics Corporation" (UTHR) at Strong Buy with Decreased Target from $231 to $203 on, Feb 25th, 2022.

Matthew has made no other calls on UTHR in the last 4 months.



There is 1 other peer that has a rating on UTHR. Out of the 1 peers that are also analyzing UTHR, all agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Julian Harrison of "BTIG" Initiated at Hold on, Friday, February 11th, 2022

Like: 👍